Legend Biotech Corporation (NASDAQ:LEGN) Q2 2024 Earnings Call Transcript August 9, 2024 8:00 AM ET
Company Participants
Jessie Yeung - VP of IR & Finance
Ying Huang - CEO
Lori Macomber - CFO
Steve Gavel - Head of Commercial Development for US and Europe
Guowei Fang - CSO
Conference Call Participants
Gena Wang - Barclays
Jessica Fye - JPMorgan
Kelly Shi - Jefferies
Ash Verma - UBS
Leonid Timashev - RBC Capital Markets
Jonathan Miller - Evercore ISI
Yaron Werber - TD Cowen
James Shin - Deutsche Bank
Vikram Purohit - Morgan Stanley
Justin Zelin - BTIG
Mitchell Kapoor - H.C. Wainwright
George Farmer - Scotiabank
Rick Bienkowski - Cantor Fitzgerald
Sean McCutcheon - Raymond James
Asthika Goonewardene - Truist
Operator
Ladies and gentlemen, thank you for standing by. Welcome to Legend Biotech's Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to turn the conference over to Jessie Yeung, Vice President of Investor Relations and Finance. Please go ahead.
Jessie Yeung
Good morning. This is Jessie Yeung, VP of Investor Relations and Finance at Legend Biotech. Thank you for joining our conference call today to review our second quarter of 2024 performance.
The second quarter has been an eventful one. We are pleased to report 18.5% sequential growth in CARVYKTI sales. More importantly, we received label expansion approvals from both FDA and EMA. Lastly, we are most excited about the survival benefits demonstrated by CARVYKTI in the second analysis of CARTITUDE-4. Nothing gives us more joy than helping patients with multiple myeloma live longer.
Joining me on today's call are Ying Huang, the company's Chief Executive Officer, and Lori Macomber, the company's Chief Financial Officer. Following the prepared remarks, we will open up the call for a Q&A. We have Guowei Fang, Chief Scientific Officer, and Steve Gavel, Head of Commercial Development for the US and Europe, joining the Q&A session.
During today's call, we will be making forward-looking statements, which are subject to risks and uncertainties that may cause our actual results to differ materially from those expressed or implied here within. These forward-looking statements are discussed in greater detail in our SEC filings, which we encourage you to read and can be found under the Investors section of our company website. Thank you.